|
Studienname/Sponsor
|
Entität(en)
|
Prüfsubstanz
|
20120252 Amgen
A Phase 1 First-in-human Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 330 Administered as Continuous Intravenous Infusion in Subjects With Myeloid Malignancies.
|
AML
|
Anti-CD33 bispezifischer AK
|
20150161 Amgen
Phase 1 First in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects With Relapsed or Refractory Multiple Myeloma and Subjects With Relapsed or Refractory Acute Myeloid Leukemia.
|
AML, Multiple Myeloma
|
MCL1 Inhibitor
|
CPDR001x2x01b Novartis
An open-label, multi-center rollover protocol for continued characterization of safety and tolerability for subjects who have participated in a Novartis-sponsored spartalizumab study as single agent or in combination with other study treatments.
|
Solide Tumore
|
Check point inhibitor
|
NP40126 Roche
A Phase 1B Study Evaluating Glofitamab (RO7082859) in Combination With Rituximab (R) or Obinutuzumab (G) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Relapsed or Refractory Non-Hodgkin Lymphoma (R/R NHL) or in Participants With Untreated Diffuse Large B-Cell Lymphoma (DLBCL).
|
DLBCL
|
Anti-CD20 bispezifischer AK
|
IMGN632-0802
A Phase 1b/2 Study of IMGN632 as Monotherapy or Combination with Venetoclax and/or Azacitidine for Patients with CD123-Positive Acute Myeloid Leukemia.
|
AML (CD123 pos.)
|
Anti-CD123 ADC
|
20180257 Amgen
A Phase 1b Open-label Study to Investigate the Safety and Pharmacoki-netics of Administration of Subcutaneous Blinatumomab for the Treatment of adults with Relapsed or Refractory B cell Precursor Acute Lympho-blastic Leukemia (R/R B-ALL).
|
ALL
|
Anti-CD19 bispezifischer AK
|
EDO-S101
Phase-I-Studie zur Untersuchung der Sicherheit, der pharmakokinetischen Profile sowie der Wirksamkeit von Tinostamutin, einem First-in-Class alkylierenden HDACi-Fusionsmolekül, bei rezidivierenden/refraktären hämatologischen Malignomen.
|
cutaneous T cell lymphoma, Hodgin-Lymphom
|
Tinostamustine pan HDAC inhibitor
|
UC02-123-01
Multicenter, open-label, adaptive design phase I trial with genetically modified T-cells carrying Universal Chimeric Antigen Receptors (UniCAR02-T) in combination with CD123 target module (TM123) for the treatment of patients with hematologic and lymphatic malignancies positive for CD12.
|
AML, B-ALL, BPDCN (CD123 pos.)
|
CD123 CAR-T-cell
|
UC02-PSMA-01
Multicenter, Open-label, Adaptive Design Phase I Trial with Genetically Modified T-cells Carrying Universal Chimeric Antigen Receptors (UniCAR02-T) in Combination with PSMA peptide Target Module (TMpPSMA) for the Treatment of Patients with Progressive Disease after Standard Systemic Therapy in Cancers with Positive PSMA Marker.
|
PSMA pos. cancer i.e. prostate cancer
|
PSMA peptide CAR-T-cell
|
20190136 Amgen994
A Phase 1, Multicenter, Open-label, Dose Exploration and Dose Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 994 Monotherapy and Combination of AMG 994 and AMG 404 in Subjects with Advanced Solid Tumors.
|
NSCLC, pancreatic cancer Mesothelioma; ovarian carcinoma
|
bispezifischer AK
|
CADPT01C12101 Novartis
A Phase Ib, multicenter, open-label dose escalation and expansion platform study of select drug combinations in adult patients with advanced or metastatic BRAF V600 colorectal cancer.
|
BRAF V600 colon cancer
|
Dabrafenib mit ERK1/2 inhibitor
|
PANTAX Scandion Oncology A/S
An open-label phase Ib prospective clinical trial to investigate safety, tolerablity and maximum tolerated dose for SCO-101 in combination with gemcitabine and nab-paclitaxel in inoperable pancreatic cancer patients.
|
Pancreatic Cancer
|
inhibitor of ATP-Binding Cassette efflux pumps and SRPK1 kinase
|
CNIS793B12201
A phase II, open label, randomized, parallel arm study of NIS793 (with and without spartalizumab) in combination with SOC chemotherapy gemcitabine/nab-paclitaxel, and gemcitabine/nab-paclitaxel alone in first-line metastatic pancreatic ductal adenocarcinoma (mPDAC).
|
Pancreatic Cancer
|
TGFB1 Inhibitor
|
Quelle: Matthias Daenschel TrickFilmProduktion
